You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
This is No 4 of a monograph's on Clinical and Experimental Psychiatry, which aims to keep track of important developments in Psychiatry, to summarize what has been achieved in particular fields and to bring together the view points obtained from disparate vantage points- to capture some of the excitement ongoing in modern psychiatry both in its clinical and experimental dimensions. This edition looks the role of Serotonin in Clinical Psychiatric Research.
Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into th...
Each year pharmaceutical companies invest billions of dollars in clinical trials of drugs used for the treatment of central nervous system diseases. Due to enormous progress in basic pharmaceutical research in recent years, controlled tests of new medications are flourishing and these trials have rapidly become an intense focus of practical medical research. Aware of the complexities presented in the design, execution, and evaluation of clinical trials, Marc Hertzman and Douglas E. Feltner bring together a collection of essays that dissect the scientific, psychosocial, political, and ethical concerns that must be examined for any CNS trial. The internationally known contributors examine conc...
None
Antipsychotic drugs were first discovered in 1953, and not since the late 1970s has the Handbook of Experimental Pharmacology taken up this topic. A new treatment of this topic would be due under any circumstances; however, this is now particularly true, since remarkable progress has been made on several fronts in furthering our understanding of the mechanisms of antipsychotic drug action. First, we have learned that schizophrenia is an illness with particu lar neuroanatomical abnormalities, many of which suggest that the illness is caused by errors in neurodevelopment. These findings have helped to form a context for understanding neurochemical aberrations in the illness and suggest new app...
Dementia: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Dementia: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Dementia: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.